Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Low level of testosterone increases risk for Alzheimer's disease

Low levels of the male sex hormone, testosterone, in older men is associated with the onset of Alzheimer's disease, according to research by a team that includes a Saint Louis University scientist.

6 Oct 2010

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced today that an independent data monitoring committee (IDMC) has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.

6 Oct 2010

MRI technique may help predict decline in individuals with mild cognitive impairment

Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.

5 Oct 2010

Caring.com introduces interactive Alzheimer’s resource for caregivers

Caring.com today launched Steps & Stages, the first-ever interactive guide, support system, and customized e-mail newsletter that delivers specific, stage-appropriate advice for those providing care for a loved one with Alzheimer's or another form of dementia.

5 Oct 2010

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.

5 Oct 2010

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

McGill University joins two leading Swiss research institutions to enhance neuroscience research

Building on its worldwide reputation as a leader in neuroscience research, McGill University today joined with two leading Swiss research institutions - the University of Zurich (UZH) and the Swiss Federal Institute of Technology (ETHZ) - to enhance neuroscience research in a host of areas, in fields that include pain therapy, Alzheimer's disease, synapse modelling and repair, neuroimmunology and genetic mechanisms of brain diseases.

5 Oct 2010

Tasly, ProteoTech to co-develop Exebryl-1(R) medication for Alzheimer's disease treatment

Tasly Pharmaceutical Co., Ltd. and ProteoTech, Inc. today announced an agreement to co-develop ProteoTech's novel small molecule therapeutic, Exebryl-1(R), for the treatment of mild-to-moderate Alzheimer's disease.

5 Oct 2010

Mayo Clinic implements Medidata Rave technology to manage multi-site clinical research studies

Mayo Clinic is making it easier for industry sponsors and investigators at sites across the country to collaborate with Mayo on complex and groundbreaking research studies and clinical trials.

5 Oct 2010

Researchers investigate ways to increase survival rate in patients with Parkinson's disease

New research shows how old people are when they first develop Parkinson's disease is one of many clues in how long they'll survive with the disease. The research is published in the October 5, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

Neuro-Biotech Corporation introduces a Neuro-biomarker which is linked to a series of Neuro-Bio tests. This will permit to understand the science behind them and how they each will contribute to a progressive clinical investigation involving the input and output of the brain.

5 Oct 2010

NIEHS awards grant to study environmental impact on genetic information

The National Institute of Environmental Health Sciences has awarded $2.27 million to Indiana University researcher Joseph Shaw for a five-year study of how the environment alters genetic information through mutation and natural selection.

5 Oct 2010

Second pathway to brain’s memory function uncovered

Australian and US scientists have successfully identified a new mechanism by which the brain learns and stores memories. This could spell hope for brain injuries and diseases like Alzheimer’s disease.

4 Oct 2010

New SymPath kit measures DBH activity of Sympathetic Nervous System

Biotech Corporation in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.

4 Oct 2010

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

A UC Irvine infectious disease specialist has received a three-year, $10 million grant to explore the effectiveness of new methods to prevent staph infections in people who harbor MRSA bacteria when they're discharged from the hospital.

4 Oct 2010

Welch Allyn launches Connex ProBP handheld automated digital blood pressure device

Welch Allyn, a leading global provider of frontline medical products and solutions, today introduced the Connex® ProBP™ 3400, an automated digital blood pressure device designed to fit in the palm of the hand. Borrowing Welch Allyn SureBP™ technology from the company's multiparameter vital signs devices, the Connex ProBP delivers fast, accurate blood pressure readings with the durability of Welch Allyn's popular hospital-grade vital signs devices.

4 Oct 2010

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

Family and friends may pose the greatest threat to caregivers' health and well-being

The biggest cause of stress for people who care for loved ones after a stroke may not be worrying about the affected family member.

1 Oct 2010

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

The pharmaceutical division of the company Neuron BPh and the research group of Organometallic Chemistry and Homogeneous Catalysis of the Universitat Jaume I, have evaluated the possible applications of a series of ruthenium compounds for their future use in the treatment of neurodegenerative disease such as Alzheimer.

30 Sep 2010

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Low level of testosterone increases risk for Alzheimer's disease

IDMC recommends early termination of Phase 3 intramuscular depot aripiprazole trial

MRI technique may help predict decline in individuals with mild cognitive impairment

Caring.com introduces interactive Alzheimer’s resource for caregivers

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Neuraltus achieves last patient out for NP001, NP002 studies

McGill University joins two leading Swiss research institutions to enhance neuroscience research

Tasly, ProteoTech to co-develop Exebryl-1(R) medication for Alzheimer's disease treatment

Mayo Clinic implements Medidata Rave technology to manage multi-site clinical research studies

Researchers investigate ways to increase survival rate in patients with Parkinson's disease

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

NIEHS awards grant to study environmental impact on genetic information

Second pathway to brain’s memory function uncovered

New SymPath kit measures DBH activity of Sympathetic Nervous System

UCI awarded $10M grant to explore ways of preventing staph infections in people harboring MRSA bacteria

Welch Allyn launches Connex ProBP handheld automated digital blood pressure device

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Family and friends may pose the greatest threat to caregivers' health and well-being

Universitat Jaume I evaluates ruthenium compounds for neurodegenerative disease treatment

Aneuro: An Overview of Neuroscience Research eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

Aneuro: An Overview of Neuroscience Research eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in